Exocell—糖尿病研究相關產品

Exocell公司是一家專注于糖尿病及其并發癥研究相關的產品與服務美國高科技生物制品公司，該公司提供先進的糖尿病研究產品，涵蓋臨床診斷、臨床研究及基礎實驗研究領域，包括人、小鼠、 大鼠尿蛋白和糖基化蛋白，人纖連蛋白、載脂蛋白B等一系列試劑盒和抗體，其高品質的產品歐美。作為開發，營銷和執行新的臨床診斷化驗*者，Exocell公司已經并且正在為糖尿病及其相關的腎臟和血管疾病領域的基礎科研、實驗動物研究以及臨床診斷和治療研究提供的產品和研發服務。

Exocell公司的主要產品：

一、臨床診斷檢測對于糖尿病及其并發癥的治療和管理至關重要，在該領域中Exocell公司提供的臨床診斷相關產品包括：

Albuwell用于檢測微白蛋白尿，是早期糖尿病性腎功能紊亂的明確標志物。

Creatinine用于檢測尿中的creatinine.

Glycaben用于監測糖化白蛋白（中期的控糖指標）

Glycacor用于檢測糖化LDL（短期控糖指標及心血管疾病風險指標）

Hemoglobin A1c參照標準（長期控糖指標）

二、臨床研發類檢測試劑與試劑盒測定大量人類糖尿病及其并發癥的重要指標，在該領域中Exocell公司提供的相關產品包括：

Apo B Test用于檢測人血漿中的apolipoprotein B

Collagen IV H用于檢測 樣本中的IV 型膠原

hFibronectin ELISA試劑盒用于檢測人血漿中的fibronectin

Nephrin ELISA試劑盒用于檢測尿液中的nephrin.

h-PODXL用于檢測人組織或尿液樣本中的podocalyxin

Beta-induced h3用于檢測人尿液中的BIG-H3，

Troponin – H用于檢測人血漿或血清中的 Troponin I，

TNF-sR2 用于檢測人尿/血漿/血清中的TNF-α可溶性受體2

三、Exocell公司提供的糖尿病及其并發癥的實驗室研究相關產品，包括：

Albuwell M用于檢測小鼠樣本中的微白蛋白尿，

Nephrat II用于檢測大鼠樣本中的微白蛋白尿，

Albuwell C, O 及 P 用于檢測狗、綿羊及非人的靈長類動物樣本中的微白蛋白尿，

Collagen IV M用于檢測小鼠和大鼠樣本中的IV型膠原，

Creatinine Companion用于檢測人和嚙齒類動物的creatinine.

Glyco-Albumin R用于檢測大鼠血清中的糖化白蛋白，

Nephrin ELISA to measure rodent urinary nephrin.

CRP ELISA試劑盒用于檢測嚙齒類動物血漿中的C-reactive蛋白.

Adiponectin ELISA試劑盒用于檢測人尿和血漿中的adiponectin，

Beta-induced h3用于檢測人尿中的BIG-H3，

Troponin M用于檢測小鼠血漿/血清中的Troponin I，

Troponin R用于檢測大鼠血漿/血清中的Troponin I，

PODXL–R用于檢測嚙齒類動物尿液中的podpcalyxin ，

四、糖尿病及其并發癥研究相關的試劑及標準參照品，包括高特異性的單克隆抗體及高度純化的蛋白，，在該領域中Exocell公司提供的相關產品包括：

A717:抗糖化白蛋白單克隆抗體

E85: 抗糖化血紅素的單克隆抗體

ES12:抗糖化LDL的單克隆抗體

糖化血紅素片段(gly Hb, HbA1c, glyHbA0, HbA1a, b)

去糖的血紅素片段(degly Hb, degly HbA0)

糖化的白蛋白(NGA/SGA)

去糖化的白蛋白

部分使用Exocell公司產品的相關文獻：

  1、Albuwell M：

• American Journal Physiology Renal Physiology 293:F1657-1665, 2007
  Interference with TGF-B signalling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria
• American Journal Physiology Renal Physiology 292:F321-329, 2007
  Soluble betaglycan reduces renal damage progression in db/db mice
• Nephron Experimental Nephrology 105:e45-e52, 2007
  Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice
• American Journal Physiology Renal Physiology 290:F214-F222, 2006
  Impact of genetic background on nephropathy in diabetic mice
• American Journal Physiology Heart Circ Physiology 290:H935-H940, 2006
  Angiotensin II hypertension is attenuated in interleukin-6 knockout mice
• American Journal Physiology Renal Physiology 291:F1315-F1322, 2006
  Characterization of diabetic nephropathy in a transgenic model of hypoinsulinemic diabetes
• American Journal Physiology Renal Physiology 290:F813-820, 2006
  SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice
• American Journal Physiology Renal Physiology 290:F828-F837, 2006
  Adenosine A2a receptor activation attenuates inflammation and injury in diabetic nephropathy
• Nephron Experimental Nephrology 104:e23-e34, 2006
  Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice
• Journal American Society Nephrology 16:27-45, 2005
  Mouse models of diabetic nephropathy
• American Society Nephrology 16:1289-1299, 2005
  Genome-wide scan in a novel IgA nephropathy model identifies a susceptibility locus on murine chromosome 10, in a region syntenic to human IGAN1 on chromosome 6q22-23
• Diabetes 54:2628-2637, 2005
  Characterization of susceptibility of inbred mouse strains to diabetic nephropathy
• American Journal Pathology 165:1243-1255, 2004
  Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules
• Hypertension 43:364-369, 2004
  Role for thromboxanes receptors in angiotensin-II-induced hypertension
• Journal Clinical Investigation 113:1390-1397, 2004
  Induction of B7-1 in podocytes is associated with nephritic syndrome
• Diabetes 53:2101-2109, 2004
  Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-?-deficient mice
• Journal American Society Nephrology 14:1200-1211, 2003
  Focal and segmental glomerulosclerosis in mice with podocyte-specific expression of mutant ?-actinin-4
• American Journal Pathology 162:1123-1137, 2003
  RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy
• Kidney International 64:1978-1985, 2003
  Gene expression profile in diabetic KK/Ta mice
• Journal of Immunology 170:5658-5666, 2003
  CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration

      2、Glycacor：

• Atherosclerosis 202:162-168, 2009
  Glycation of LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro
• Immunopharmacology Immunotoxicology 15:1-12, 2008
  Evaluation of serum biomarkers in nutritional disorders: Glycated apolipoprotein B, fasting serum glucose, fructosamine, stable and labile glycated hemoglobin in diabetic and non-diabetic subjects
• Nutrition Metabolism & Cardiovascular Disease 17:6-12, 2007
  Glycated apolipoprotein B and myocardial infarction
• Circulation 109:1750-1755, 2004
  Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes
• Diabetes Technology & Therapeutics 6:348-356, 2004
  Increased plasma glycated low-density lipoprotein concentrations in diabetes: A marker of atherogenic risk
• Journal American Society Nephrology 10:332-341, 1999
  Non-insulin dependent diabetes mellitus and hypertriglyceridemia impair lipoprotein metabolism in chronic hemodialysis patients
• Nephrology Dialysis Transplantation 12:1336-1343, 1997
  Uptake and metabolism of lipoproteins from patients with diabetes mellitus type II by glomerular epithelial cells

3、Nephrat：

• Cell Biochemistry Biophysics 48:147-157, 2007
  Novel inhibitors of glycation and AGE formation
• American Journal Physiology Regul Integr Comp Physiology 292:R769-R777, 2007
  17-estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney
• Diabetes 56:1842-1849, 2007
  Hyperglycemia is a major determinant of albumin permeability in diabetic microcirculation
• American Journal Physiology Renal Physiology 290:F828-F837, 2006
  Adenosine A2a receptor activation attenuates inflammation and injury in diabetic nephropathy
• Laboratory Investigation 86:357-368, 2006
  Expression of Smad1 is directly associated with mesangial matrix expansion in rat diabetic nephropathy
• FASEB Journal 20:E150-E159, 2006
  Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers
• American Journal Physiology Regul Integr Comp Physiology 290:R435-R441, 2006
  Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes
• Laboratory Investigation 86:927-939, 2006
  Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy
• American Journal Physiology Renal Physiology 289:F442-450, 2005
  Regulation of the renal thiazide-sensitive Na-Cl cotransporter, blood pressure, and natriuresis in obese Zucker rats treated with rosiglitazone
• Diabetologia 46:1140-1152, 2003
  LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats
• Journal American Society Nephrology 14:709-720, 2003
  Delayed treatment with lithospermate B attenuates experimental diabetic renal injury
• Journal American Society Nephrology 14:3178-3187, 2003
  Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen ?5(IV) in experimental diabetic nephropathy and ion glucose-stimulated podocytes
• American Journal Pathology 158:1733-1741, 2001
  A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis
• American Journal Society Nephrology 12:993-1000, 2001
  Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes

      4、Collagen Type IV

• Diabetologia 51:198-207, 2008
  Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells
• Nephron Experimental Nephrology 105:e45-e52, 2007
  Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice
• American Journal Physiology Renal Physiol 292:F789-F795, 2007
  Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and collagen IV subchain production and the development of renal insufficiency
• American Journal Physiology Renal Physiology 290:F813-820, 2006
  SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice
• Kidney International 68:1554-1561, 2005
  Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy
• Kidney International 64:1632-1642, 2003
  Vitamin D3 up-regulated protein-1 regulates collagen expression in mesangial cells
• Metabolism 50:1435-1440, 2001
  Increased urinary type IV collagen marks the development of glomerular [athology in diabetic db/db mice
• Diabetes Care 24:914-918, 2001
  Increased collagen IV excretion in diabetes
• Diabetes Care 24:1324-1327, 2001
  Serum type IV collagen in diabetic patients at risk for nephropathy

5、Nephrin：

• PLoS One 7(5):e36041, 2012
  Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: A cross sectional study
• Am J Physiol Renal Physiol 302:F1084-F1089, 2012
  Increased urinary excretion of nephrin, podocalyxin and ?ig-h3 in women with preeclampsia

6、Podocalyxin：

• Am J Physiol Renal Physiol 302:F1084-F1089, 2012
  Increased urinary excretion of nephrin, podocalyxin and βig-h3 in women with preeclampsia

7、 βig-h3：

• Am J Physiol Renal Physiol 302:F1084-F1089, 2012
  Increased urinary excretion of nephrin, podocalyxin and βig-h3 in women with preeclampsia

詳細公司及產品信息請訪問：http://www.exocell。。ｃｏｍ/

世界*實驗材料供應商Exocell正式授權上海起發為其中國代理，Exocell在一直是行業的*,一直為廣大科研客戶提供zui為的產品和服務,上海起發一直秉承為中國科研客戶帶來的產品，的服務， 簽約Exocell就是為了給廣大科研客戶帶來更加完善的產品和服務,您的滿意將是我們zui大的收獲

Exocell中國代理，Exocell上海代理，Exocell北京代理，Exocell廣東代理，Exocell江蘇代理 Exocell湖北代理, Exocell天津, Exocell黑龍江代理, Exocell內蒙古代理, Exocell吉林代理, Exocell福建代理, Exocell江蘇代理, Exocell浙江代理, Exocell四川代理,

我們公司zui大優勢是強大的采購，

1：基本什么都能進口，血清，抗體，耗材，還有部分限制進口的，

2： 貨品全，現經營過700多個品牌，基本所有生物試劑耗材都可以進口，特別是冷偏的產品那就更有優勢，

3：提供加急服務，一般1-2周到貨，超過時限加急費全免

4：價格公道，絕大部分價格有優勢，當然不能保證100%產品都是,因為意味著沒有服務.

5：良好的信譽，大部分客戶我們提供貨到付款服務，客戶包括清華，北大 交大 復旦，中山等100多所大學，ROCHE，阿斯利康，國藥 ，fisher等500多家公司

6：我們還是santa,Advanced Biotechnologies Inc;Athens Research & Technology, bangs, BBInternational, crystalchem, dianova, FD Neurotechnologies, Inc. FormuMax Scientific, Inc; Genebridege; Glycotope Biotechnology GmbH; iduron; Innovative Research of America； Ludger ； neuroprobe; omicronbio; Polysciences; prospecbi; QA-BIO；quickzyme；RESEARCH DIETS, INC；sterlitech；sysy；TriLink BioTechnologies, Inc；worthington-biochem;zyagen;......幾十家國外公司授權代理

7：我們還從事invitrogen，qiagen; abcam ;sigma;neb; roche;merck; rnd; BD; GE; pierce; BioLegend....等*批發